• Publications
  • Influence
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale
&NA; Pain intensity is frequently measured on an 11‐point pain intensity numerical rating scale (PI‐NRS), where 0=no pain and 10=worst possible pain. However, it is difficult to interpret theExpand
  • 3,797
  • 106
  • PDF
Pregabalin for the treatment of postherpetic neuralgia
Objective: To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN). Methods: The authors conducted a multicenter, parallel-group, double-blind,Expand
  • 736
  • 26
Pregabalin relieves symptoms of painful diabetic neuropathy
Objective: Pregabalin, an alpha2-delta ligand with analgesic, anxiolytic, and anticonvulsant activity, has been evaluated for treatment of neuropathic pain. The authors assessed the efficacy andExpand
  • 538
  • 19
Belinostat: First Global Approval
Belinostat [Beleodaq® (US)], a small-molecule hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals forExpand
  • 104
  • 7
Pembrolizumab: First Global Approval
Pembrolizumab [Keytruda® (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer. Pembrolizumab hasExpand
  • 81
  • 5
Tofogliflozin: First Global Approval
Tofogliflozin (Apleway®, Deberza® [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment ofExpand
  • 54
  • 3
Selective publication of antidepressant trials.
  • 41
  • 3
Eliglustat: First Global Approval
Eliglustat [Cerdelga™ (US, EU)], a small-molecule oral glucosylceramide analogue that inhibits the enzyme glucosylceramide synthase has been developed by Genzyme Corporation (a subsidiary of Sanofi)Expand
  • 32
  • 3
Ipragliflozin: First Global Approval
Ipragliflozin (Suglat® [Japan]), an orally active, next-generation sodium-glucose transporter 2 (SGLT2) inhibitor, has been developed by Astellas Pharma and Kotobuki Pharmaceutical for the treatmentExpand
  • 84
  • 2
Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke.
BACKGROUND AND PURPOSE We sought (1) to compare the frequency and severity of asymptomatic coronary artery disease (CAD) in patients with different causes of brain ischemia and (2) to determineExpand
  • 81
  • 1
...
1
2
3
4
5
...